Sartorius Stedim: 9m net income plummets

(CercleFinance.com) - Sartorius Stedim Biotech reported net income that fell by over half (-53.
5%) to E129m for the 9m 2024, with recurring EBITDA down 4.9% to E565m, representing a margin down 0.9 point to 27.8%.

The supplier of products and services to the pharmaceutical industry posted sales of E2.03bn, down 1.9% (-3% organically and at constant exchange rates), but its order intake rose by 7.7% to over E1.89bn.

Based on these results, management confirms its forecasts for 2024, i.e. sales remaining broadly at the previous year's level, and a current EBITDA margin expected to reach 27%-29%.


Copyright (c) 2024 CercleFinance.com. All rights reserved.